We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


ProBioGen, Eucodis Sign Agreement

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

ProBioGen and Eucodis Bioscience have announced the signature of an exclusive license agreement on C-LiNK (CTAT), an innovative, site-specific ADC conjugation technology. Under the agreement ProBioGen gains exclusive rights to commercialize Eucodis’ enzymatic C-terminal linking technology, and to offer it, together with its antibody development services, royalty-free to ADC-developing parties.

ProBioGen’s CEO, Dr. Wieland Wolf, commented: “This agreement is an excellent match between Eucodis’ enzyme engineering expertise and ProBioGen’s therapeutic protein-optimizing technologies and we look much forward to position C-LiNK and our contract manufacturing services right in the middle of the hot ADC field”.

Dr. Karl Hübler, CEO of Eucodis explained: “We see a huge potential for C-LiNK in Biopharma, especially in ADC development, but our expertise is engineering enzymes. Therefore, by teaming up with ProBioGen, our ADC conjugation technology will certainly get a much wider and quicker access to the community of therapeutic protein developing companies and we are convinced that our agreement with ProBioGen will result in fruitful collaborations within the industry.”

ProBioGen’s Chief Scientific Officer, Dr. Volker Sandig, added: “This innovative ADC technology, which efficiently attaches any payload enzymatically via a pure peptide linker -as short as two amino acids-, blends perfectly into our portfolio of robust cell line/product engineering technologies and manufacturing capabilities. The 1-step C-LiNK coupling technology will further open up the development space for ADCs and represents a competitive alternative to other Antibody-Drug Conjugate Technologies.”

Dr. Jan Modregger, Eucodis’ Head of R&D stated: “Based on a trypsin variant engineered to enforce formation of a new peptide bond, our ADC conjugation technology links toxins or other molecules to the C-terminus of either antibody chain, without disturbing the native antibody structure. The outcome is a defined Drug-Antibody Ratio at high yield with low enzyme requirements and it offers on top the flexibility to add different payloads to separate sites in future ADCs.”